APT Pharmaceutical

APT Pharmaceuticals, founded in 2005, is a drug research and development company located in California that focuses on treating severe pulmonary diseases. They have developed a strong understanding of patented pharmaceutical formulations related to severe lung conditions to mitigate risks. With robust Phase II data and a promising Phase III study, the inhaled cyclosporine program has the potential to transform lung transplantation practices in the near future.